Eisai Co., Ltd. announced that the European Medicines Agency (EMA) has accepted the marketing authorization application for lemborexant, its orexin receptor antagonist, intended for treating chronic insomnia in adults. Lemborexant, a dual orexin receptor antagonist (DORA), targets the orexin neurotransmitter system, which regulates sleep and wakefulness. By competitively binding to orexin receptors OX1R and OX2R, lemborexant is believed to aid […]